Abstract: The present invention relates to 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer.
Type:
Grant
Filed:
January 17, 2014
Date of Patent:
March 22, 2016
Assignee:
MERCK PATENT GMBH
Inventors:
Axel Becker, Clemens Kuehn, Christoph Saal, Oliver Schadt, Dieter Dorsch, Heinz-Hermann Bokel, Frank Stieber, Cristina Donini
Abstract: The present invention relates to a thin-layer chromatography plate at least consisting of a support and a sorbent layer, where the sorbent layer comprises at least one siloxane oligomer, to a process for the production thereof, and to a method for carrying out a thin-layer chromatographic separation using said thin-layer chromatography plate.
Abstract: Compounds of formula (I) and their uses as inhibitors of tyrosine kinases, in particular Met kinase, and their employment in methods for the treatment of tumors.
Type:
Grant
Filed:
September 25, 2014
Date of Patent:
March 15, 2016
Assignee:
Merck Patent GmbH
Inventors:
Dieter Dorsch, Frank Stieber, Oliver Schadt, Andree Blaukat
Abstract: The invention relates to novel polymers containing repeating units based on thieno[3,4-b]thiophene, monomers and methods for their preparation, their use as semiconductors in organic electronic (OE) devices, especially in organic photovoltaic (OPV) devices, and to OE and OPV devices comprising these polymers.
Type:
Grant
Filed:
June 14, 2011
Date of Patent:
March 15, 2016
Assignee:
Merck Patent GmbH
Inventors:
Nicolas Blouin, William Mitchell, Miguel Carrasco-Orozco, Frank Egon Meyer, Steven Tierney
Abstract: Compounds of the formula I in which Het, R3 and R4 have the meanings indicated in Claim 1, are inhibitors of RON and can be employed, for the treatment of cancer.
Type:
Grant
Filed:
June 15, 2012
Date of Patent:
March 15, 2016
Assignee:
Merck Patent GmbH
Inventors:
Wolfgang Staehle, Oliver Schadt, Christine Knuehl, Manja Friese-Hamim, Bayard R. Huck, Andreas Goutopoulos, Nadia Brugger
Abstract: The invention relates to novel polymers containing repeating units based on benzodifuran, benzodipyrrole or benzodithiophene, monomers and methods for their preparation, their use as semiconductors in organic electronic (OE) devices, especially in organic photovoltaic (OPV) devices, and to OE and OPV devices comprising these polymers.
Type:
Grant
Filed:
June 14, 2011
Date of Patent:
March 15, 2016
Assignee:
Merck Patent GmbH
Inventors:
Nicolas Blouin, Steven Tierney, William Mitchell, Miguel Carrasco-Orozco, Frank Egon Meyer
Abstract: The present invention relates to the use of at least one tertiary amine-N-oxide of formula I as additive in dye-sensitized solar cells and to special electrolyte formulations and a dye-sensitized solar cell comprising at least one compound of formula I.
Abstract: The invention is directed to the treatment of lung cancer, preferably non-small cell lung cancer (NSCLC) by means of a combination therapy comprising concurrent chemo-radiotherapy followed by vaccination with a muc-1 lipopetide. The therapy elicits prolonged survival rates compared to a respective therapy including sequential chemo-radiotherapy.
Type:
Application
Filed:
April 14, 2014
Publication date:
March 10, 2016
Applicant:
MERCK PATENT GmbH
Inventors:
Andreas SCHROEDER, Christoph HELWIG, Anja-Helena LOOS, Armin SCHUELER, Martin FALK, Charles BUTTS, Frances A. SHEPHERD
Abstract: The invention relates to a layer or article comprising cholesteric liquid crystal polymer particles, which are optionally dispersed in a continuous phase, to cholesteric polymer particles for use in such a layer or article, to methods of preparing such a layer or article, and to the use of such a layer or article as optical element, in windows or electrooptical devices like liquid crystal displays (LCDs).
Type:
Application
Filed:
March 19, 2014
Publication date:
March 10, 2016
Applicant:
MERCK PATENT GMBH
Inventors:
Eduardo BELTRAN GRACIA, Owain Llyr PARRI
Abstract: Polymerizable compounds, to processes and intermediates for the preparation thereof, and to the use thereof for optical, electro-optical and electronic purposes, in particular in liquid-crystal (LC) media and LC displays, especially in LC displays of the PS (“polymer sustained”) or PSA (“polymer sustained alignment”) type.
Type:
Grant
Filed:
December 27, 2011
Date of Patent:
March 8, 2016
Assignee:
Merck Patent GmbH
Inventors:
Andreas Taugerbeck, Achim Goetz, Alexander Hahn, Martin Engel
Abstract: The invention relates to compounds of the formula I, in which X1, X2, Sp, and R are as defined herein, and to the use thereof in liquid-crystal media, but also to the use of these liquid-crystal media in liquid-crystal displays, and also to liquid-crystal displays of this type per se.
Type:
Application
Filed:
August 31, 2015
Publication date:
March 3, 2016
Applicant:
MERCK PATENT GMBH
Inventors:
Achim GOETZ, Rocco FORTTE, Martin ENGEL, Sabrina MAAG, Ingo ALMEROTH, Thomas MERGNER, Thorsten KODEK, Detlef PAULUTH
Abstract: The present invention relates to a temperature-reactive device for the regulation of light transmission, containing a liquid-crystalline medium and a compound of formula I, capable of promoting or inducing homeotropic alignment to the adjacent liquid crystal medium at a given temperature. The invention furthermore relates to a process for the temperature-dependent control of light transmission through a layer of a liquid-crystalline medium.
Abstract: Compounds of the formula (I) in which R, R1 and X have the meanings indicated in claim 1, are inhibitors of TBK1 and IKK? and can be employed, inter alia, for the treatment of cancer and inflammatory diseases
Type:
Grant
Filed:
April 11, 2012
Date of Patent:
March 1, 2016
Assignee:
Merck Patent GmbH
Inventors:
Guenter Hoelzemann, Hans-Michael Eggenweiler, Srinivasa R. Karra
Abstract: The invention relates to co-activated magnesium alumosilicate based phosphors, to a process of its preparation, the use of these phosphors in electronic and electro optical devices, such as light emitting diodes (LEDs) and solar cells and especially to illumination units comprising said magnesium alumosilicate-based phosphors.
Abstract: The present invention relates to a liquid crystal (LC) medium comprising a polymerisable compound, one or more compounds of formula Q, and one or more compounds of formula AN1 to a process for its preparation, to its use for optical, electro-optical and electronic purposes, in particular in LC displays, especially in an LC display of the polymer sustained alignment (PSA) type, and to an LC display, especially a PSA display, comprising it.
Type:
Application
Filed:
August 17, 2015
Publication date:
February 25, 2016
Applicant:
MERCK PATENT GMBH
Inventors:
Dong-Mee SONG, Eun-Kyu LEE, Seung-Eun LEE
Abstract: The present invention relates to polymerizable compounds, to processes and intermediates for the preparation thereof, to liquid-crystal (LC) media comprising them, and to the use of the polymerizable compounds and LC media for optical, electro-optical and electronic purposes, in particular in LC displays, especially in LC displays of the polymer sustained alignment type.
Type:
Application
Filed:
August 24, 2015
Publication date:
February 25, 2016
Applicant:
MERCK PATENT GMBH
Inventors:
Qiong TONG, Nico SCHWEBEL, Eveline BARON, Christoph MARTEN
Abstract: The invention relates to a liquid-crystalline medium which comprises at least one compound of the formula I, wherein the radicals R11, L1, L2, n and A are as defined herein, and to the use thereof for an active-matrix display, in particular based on the VA, PSA, PS-VA, PA-VA, PALC, FFS, PS-FFS, IPS or PS-IPS effect.
Type:
Application
Filed:
August 21, 2015
Publication date:
February 25, 2016
Applicant:
MERCK PATENT GMBH
Inventors:
Harald HIRSCHMANN, Martina WINDHORST, Monika BAUER, Volker REIFFENRATH, Matthias BREMER
Abstract: The present invention relates to a liquid-crystalline medium based on a mixture of polar compounds having negative dielectric anisotropy (??), which is distinguished by the fact that it has a value for the ratio ?1/?n2 in the range 6-45 with a clearing point of >60° C. and a ?? of ??2.3. Media of this type are particularly suitable for electro-optical displays having active-matrix addressing based on the ECB, PA LCD, FFS or IPS effect.
Abstract: Compounds of the formula (I) in which R, R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of tumors.
Type:
Grant
Filed:
February 6, 2015
Date of Patent:
February 23, 2016
Assignee:
Merck Patent GmbH
Inventors:
Dieter Dorsch, Christian Sirrenberg, Thomas J. J. Mueller, Eugen Merkul, Gnuni Amatunu Karapetyan
Abstract: The invention relates to a liquid-crystalline medium based on a mixture of polar compounds which contains at least one compound of the formula I, and at least one additional compound, and to the use of the LC mixtures for an active- or passive matrix addressed displays, in particular based on the VA, PSA, PS-VA, IPS, FFS, PS-IPS, PS-FFS technology, preferably in optical displays for the self-aligning VA mode.